Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants — clinical, public health, and vaccine implications. N Engl J Med. DOI: 10.1056/NEJMc2100362

References associated with Table 1.

Ad26.COV2.S (Johnson & Johnson)

Johnson & Johnson. Press release: Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. available from: https://www.janssen.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-metprimary-endpoints. accessed: 9 February 2021; 2021.

BNT162b2 (Pfizer)

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Eng J Med 2020;383:2603-15.

BNT162b2 (Pfizer) and mRNA-1273 (Moderna)

Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 2021:2021.2001.2025.428137.

Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM*, et al.* Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*. DOI: https://doi.org/10.1016/j.cell.2021.1003.1013.

mRNA-1273 (Moderna)

Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv : the preprint server for biology 2021.

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Eng J Med 2020;384:403-16.

Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv 2021:2021.2001.2027.428516.

Sputnik V (Gamaleya)

Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. https://doi.org/10.1016/S0140-6736(21)00234-8

AZD1222 (AstraZeneca)

Madhi SA, Baillie V, Cutland CL, *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine* 2021: DOI: 10.1056/NEJMoa2102214.

Voysey M, Sue Ann Costa Clemens SAC, Madhi SA, et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. Lancet pre-print 2020: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268

NVX-CoV2373 (Novavax)

Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv 2021:2021.2001.2027.428516.

Novavax. Press release: Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Accessed: 9 February 2021. 2021.

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0

CoronaVac (Sinovac)

Reuters. Press release: China approves Sinovac Biotech COVID-19 vaccine for general public use. Available from: https://www.reuters.com/article/us-health-coronavirus-vaccine-sinovac-idUSKBN2A60AY. Accessed: 9 February 2021. 2021.

Daily Sabah with agencies. Turkey set to receive 'effective' COVID-19 vaccine amid calls for inoculation. Available from: https://www.dailysabah.com/turkey/turkey-set-to-receive-effective-covid-19-vaccine-amid-calls-for-inoculation/news

BBIBP-CorV (Sinopharm)

Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv preprint 2021:https://doi.org/10.1101/2021.02.01.429069.

Wee, Sui-Lee; Qin, Amy (2020-12-30). "China Approves Covid-19 Vaccine as It Moves to Inoculate Millions". The New York Times. Available from: https://www.nytimes.com/2020/12/30/business/china-vaccine.html